Physician profile

Landon Simpkins

New Orleans, LA

NPI 1619556024

$524.31

in general payments reported to CMS, 2019-2025

6 companies · $94.01 in 2025

The $94.01 reported for 2025 was less than what a typical provider received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$524.31

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Ucb, INC. $255.55 2023-2025 Briviact, Fintepla
Jazz Pharmaceuticals INC. $117.69 2023-2025 Epidiolex
Abbvie INC. $92.14 2023-2024 Qulipta, Duopa, Botox
Neurelis, INC. $26.82 2024 Valtoco
Pfizer INC. $17.89 2023
Biogen, INC. $14.22 2023 Avonex, Vumerity, Plegridy

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Landon Simpkins

$524.31

in general payments reported 2019-2025

Years
2023-2025
Top company
Ucb, INC.
Context
The $94.01 reported for 2025 was less than what a typical provider received nationally.

https://glasscript.com/doctor/11552166/landon-simpkins

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.